
News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 15, 2021IND application for lead program candidate, THE-630, cleared by U.S. Food and Drug Administration; initiation of Phase 1/2 clinical trial expected between late fourth quarter 2021 and mid-first quarter 2022